JP2010522765A - 受容体チロシンキナーゼとしてのイミダゾ[1,2−a]ピリジン化合物 - Google Patents

受容体チロシンキナーゼとしてのイミダゾ[1,2−a]ピリジン化合物 Download PDF

Info

Publication number
JP2010522765A
JP2010522765A JP2010501214A JP2010501214A JP2010522765A JP 2010522765 A JP2010522765 A JP 2010522765A JP 2010501214 A JP2010501214 A JP 2010501214A JP 2010501214 A JP2010501214 A JP 2010501214A JP 2010522765 A JP2010522765 A JP 2010522765A
Authority
JP
Japan
Prior art keywords
alkyl
mmol
formula
compound
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010501214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010522765A5 (enExample
Inventor
フレデリック ピー. マームサテール,
マーク シー. マンソン,
ジェイムス ピー. リッジ,
ジョン イー. ロビンソン,
スティーブン ティー. シュラクター,
ジョージ ティー. トパロフ,
キアン チャオ,
ジョセフ ピー. リシカトス,
Original Assignee
アレイ バイオファーマ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレイ バイオファーマ、インコーポレイテッド filed Critical アレイ バイオファーマ、インコーポレイテッド
Publication of JP2010522765A publication Critical patent/JP2010522765A/ja
Publication of JP2010522765A5 publication Critical patent/JP2010522765A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010501214A 2007-03-28 2008-03-27 受容体チロシンキナーゼとしてのイミダゾ[1,2−a]ピリジン化合物 Pending JP2010522765A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90855607P 2007-03-28 2007-03-28
PCT/US2008/058385 WO2008121687A2 (en) 2007-03-28 2008-03-27 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2010522765A true JP2010522765A (ja) 2010-07-08
JP2010522765A5 JP2010522765A5 (enExample) 2012-03-22

Family

ID=39731287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010501214A Pending JP2010522765A (ja) 2007-03-28 2008-03-27 受容体チロシンキナーゼとしてのイミダゾ[1,2−a]ピリジン化合物

Country Status (7)

Country Link
US (1) US20100144751A1 (enExample)
EP (1) EP2139888A2 (enExample)
JP (1) JP2010522765A (enExample)
CN (1) CN101679422A (enExample)
CA (1) CA2682231A1 (enExample)
TW (1) TW200843757A (enExample)
WO (1) WO2008121687A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500277A (ja) * 2008-08-19 2012-01-05 アレイ バイオファーマ、インコーポレイテッド Pimキナーゼ阻害剤としてのトリアゾロピリジン化合物
JP2014509322A (ja) * 2011-02-25 2014-04-17 アレイ バイオファーマ、インコーポレイテッド Pimキナーゼ阻害剤としてのトリアゾロピリジン化合物
JP2015531371A (ja) * 2012-09-28 2015-11-02 ヴァンダービルト ユニバーシティーVanderbilt University 選択的bmp阻害剤としての縮合複素環化合物

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5374492B2 (ja) * 2007-04-03 2013-12-25 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害薬としてのイミダゾ[1,2−a]ピリジン化合物
WO2009068567A1 (en) 2007-11-30 2009-06-04 Novartis Ag C2-c5-alkyl-imidazole-bisphosphonates
US8557809B2 (en) 2008-08-19 2013-10-15 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
US8895550B2 (en) 2008-08-19 2014-11-25 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
US8987251B2 (en) 2008-08-19 2015-03-24 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
US8377924B2 (en) 2009-01-21 2013-02-19 Rigel Pharmaceuticals Inc. Protein kinase C inhibitors and uses thereof
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
AU2010311511B2 (en) 2009-10-30 2014-07-17 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
EP2332917B1 (en) * 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Compounds for PIM kinase inhibition and for treating malignancy
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CA2814826C (en) 2010-11-17 2019-02-12 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
CN103619846B (zh) 2011-06-27 2016-08-17 詹森药业有限公司 1-芳基-4-甲基-[1,2,4]三唑[4,3-a]喹喔啉衍生物
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
AU2012322095B2 (en) 2011-10-14 2017-06-29 Ambit Biosciences Corporation Heterocyclic compounds and use thereof as modulators of type III receptor tyrosine kinases
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
EP2863909B1 (en) 2012-06-26 2020-11-04 Janssen Pharmaceutica N.V. Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
ES2607184T3 (es) 2012-07-09 2017-03-29 Janssen Pharmaceutica, N.V. Inhibidores de la enzima fosfodiesterasa 10
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
HUE050215T2 (hu) 2013-01-15 2020-11-30 Incyte Holdings Corp Pim kináz inhibitorokként hasznos tiazolkarboxamid és piridinkarboxamid vegyületek
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作pim激酶抑制劑之呋喃并-及噻吩并-吡啶甲醯胺化合物
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
CN104597194B (zh) * 2015-01-15 2016-07-06 武汉轻工大学 3-氯-1,2-丙二醇的高效液相色谱-荧光检测方法
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
KR102782563B1 (ko) 2017-10-18 2025-03-14 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 이미다조-피리딘 화합물
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
HUE067265T2 (hu) 2017-11-24 2024-10-28 Jubilant Episcribe Llc Heterociklusos vegyületek mint PRMT5 inhibitorok
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3765453A1 (en) 2018-03-13 2021-01-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
US10745400B2 (en) 2018-03-14 2020-08-18 Vanderbuilt University Inhibition of BMP signaling, compounds, compositions and uses thereof
CN110833556A (zh) * 2018-08-15 2020-02-25 广西梧州制药(集团)股份有限公司 吡唑并嘧啶衍生物在治疗肝纤维化的用途
CA3190172A1 (en) * 2020-08-05 2022-02-10 The General Hospital Corporation Salt inducible kinase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515603A (ja) * 1999-11-30 2003-05-07 ファイザー・プロダクツ・インク 抗増殖剤として有用な新規ベンゾイミダゾール誘導体
JP2005530745A (ja) * 2002-05-02 2005-10-13 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
JP2007502776A (ja) * 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Rtk阻害剤としての6−置換アニリノプリン類

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256309A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515603A (ja) * 1999-11-30 2003-05-07 ファイザー・プロダクツ・インク 抗増殖剤として有用な新規ベンゾイミダゾール誘導体
JP2005530745A (ja) * 2002-05-02 2005-10-13 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
JP2007502776A (ja) * 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Rtk阻害剤としての6−置換アニリノプリン類

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500277A (ja) * 2008-08-19 2012-01-05 アレイ バイオファーマ、インコーポレイテッド Pimキナーゼ阻害剤としてのトリアゾロピリジン化合物
JP2014509322A (ja) * 2011-02-25 2014-04-17 アレイ バイオファーマ、インコーポレイテッド Pimキナーゼ阻害剤としてのトリアゾロピリジン化合物
JP2015531371A (ja) * 2012-09-28 2015-11-02 ヴァンダービルト ユニバーシティーVanderbilt University 選択的bmp阻害剤としての縮合複素環化合物
US9738636B2 (en) 2012-09-28 2017-08-22 Vanderbilt University Fused heterocyclic compounds as selective BMP inhibitors
US10196392B2 (en) 2012-09-28 2019-02-05 Vanderbilt University Fused heterocyclic compounds as selective BMP inhibitors

Also Published As

Publication number Publication date
CA2682231A1 (en) 2008-10-09
TW200843757A (en) 2008-11-16
CN101679422A (zh) 2010-03-24
US20100144751A1 (en) 2010-06-10
WO2008121687A2 (en) 2008-10-09
WO2008121687A3 (en) 2008-11-20
EP2139888A2 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
JP2010522765A (ja) 受容体チロシンキナーゼとしてのイミダゾ[1,2−a]ピリジン化合物
TWI429434B (zh) 作為受體酪胺酸激酶抑制劑之咪唑并〔1,2-a〕吡啶化合物
TWI527813B (zh) 作為III型受體酪胺酸激酶抑制劑之經取代N-(1H-吲唑-4-基)咪唑并 [1,2-a]吡啶-3-甲醯胺化合物
TWI853802B (zh) 作為a2a/a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
DK2861595T5 (en) Substituted tricyclic compounds as FGFR inhibitors
JP6039585B2 (ja) Pimキナーゼ阻害剤としてのトリアゾロピリジン化合物
CN104520290B (zh) 酰氨基螺环酰胺和磺酰胺衍生物
TW202446371A (zh) 2-氮雜雙環[2.2.1]庚烷kras抑制劑
TW202216720A (zh) 作為雄激素受體調節劑的吲哚化合物
AU2005295091A1 (en) Substituted biaryl quinolin-4-ylamine analogues
TWI863003B (zh) 經取代的 1H-吡唑并[4,3-c]喹啉、製備方法及其用途
HK1140200B (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130627